|
1
|
Nikiforov YE: Thyroid carcinoma: Molecular
pathways and therapeutic targets. Mod Pathol. 21 Suppl 2:S37–S43.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Murray T, Xu J
and Thun MJ: Cancer statistics, 2007. CA Cancer J Clin. 57:43–66.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Pacini F, Schlumberger M, Dralle H, Elisei
R, Smit JW and Wiersinga W; European Thyroid Cancer Taskforce, :
European consensus for the management of patients with
differentiated thyroid carcinoma of the follicular epithelium. Eur
J Endocrinol. 154:787–803. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zheng T, Holford TR, Chen Y, Ma JZ,
Flannery J, Liu W, Russi M and Boyle P: Time trend and
age-period-cohort effect on incidence of thyroid cancer in
Connecticut, 1935–1992. Int J Cancer. 67:504–509. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu S, Semenciw R, Ugnat AM and Mao Y:
Increasing thyroid cancer incidence in Canada, 1970–1996: Time
trends and age-period-cohort effects. Br J Cancer. 85:1335–1339.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xing M: Molecular pathogenesis and
mechanisms of thyroid cancer. Nat Rev Cancer. 13:184–199. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Begum S, Rosenbaum E, Henrique R, Cohen Y,
Sidransky D and Westra WH: BRAF mutations in anaplastic thyroid
carcinoma: Implications for tumor origin, diagnosis and treatment.
Mod Pathol. 17:1359–1363. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ji S, Ye G, Zhang J, Wang L, Wang T, Wang
Z, Zhang T, Wang G, Guo Z, Luo Y, et al: miR-574-5p negatively
regulates Qki6/7 to impact beta-catenin/Wnt signalling and the
development of colorectal cancer. Gut. 62:716–726. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kondo T, Furuta T, Mitsunaga K, Ebersole
TA, Shichiri M, Wu J, Artzt K, Yamamura K and Abe K: Genomic
organization and expression analysis of the mouse qkI locus. Mamm
Genome. 10:662–669. 1999.PubMed/NCBI
|
|
10
|
Pilotte J, Larocque D and Richard S:
Nuclear translocation controlled by alternatively spliced isoforms
inactivates the QUAKING apoptotic inducer. Genes Dev. 15:845–858.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Biedermann B, Hotz HR and Ciosk R: The
Quaking family of RNA-binding proteins: Coordinators of the cell
cycle and differentiation. Cell Cycle. 9:1929–1933. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Larocque D, Galarneau A, Liu HN, Scott M,
Almazan G and Richard S: Protection of p27(Kip1) mRNA by quaking
RNA binding proteins promotes oligodendrocyte differentiation. Nat
Neurosci. 8:27–33. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chénard CA and Richard S: New implications
for the QUAKING RNA binding protein in human disease. J Neurosci
Res. 86:233–242. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yang G, Fu H, Zhang J, Lu X, Yu F, Jin L,
Bai L, Huang B, Shen L, Feng Y, et al: RNA-binding protein quaking,
a critical regulator of colon epithelial differentiation and a
suppressor of colon cancer. Gastroenterology. 138:231–240.e1-5.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fan M, Li X, Jiang W, Huang Y, Li J and
Wang Z: A long non-coding RNA, PTCSC3, as a tumor suppressor and a
target of miRNAs in thyroid cancer cells. Exp Ther Med.
5:1143–1146. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Melo SA and Esteller M: Dysregulation of
microRNAs in cancer: Playing with fire. FEBS Lett. 585:2087–2099.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Barker N and Clevers H: Mining the Wnt
pathway for cancer therapeutics. Nat Rev Drug Discov. 5:997–1014.
2006. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Futaki S, Suzuki T, Ohashi W, Yagami T,
Tanaka S, Ueda K and Sugiura Y: Arginine-rich peptides. An abundant
source of membrane-permeable peptides having potential as carriers
for intracellular protein delivery. J Biol Chem. 276:5836–5840.
2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Raymond CK, Roberts BS, Garrett-Engele P,
Lim LP and Johnson JM: Simple, quantitative primer-extension PCR
assay for direct monitoring of microRNAs and short-interfering
RNAs. RNA. 11:1737–1744. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Galarneau A and Richard S: Target RNA
motif and target mRNAs of the Quaking STAR protein. Nat Struct Mol
Biol. 12:691–698. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
25
|
Shenouda SK and Alahari SK: MicroRNA
function in cancer: Oncogene or a tumor suppressor? Cancer
Metastasis Rev. 28:369–378. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li Q, Li X, Guo Z, Xu F, Xia J, Liu Z and
Ren T: MicroRNA-574-5p was pivotal for TLR9 signaling enhanced
tumor progression via down-regulating checkpoint suppressor 1 in
human lung cancer. PLoS One. 7:e482782012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Noveroske JK, Lai L, Gaussin V, Northrop
JL, Nakamura H, Hirschi KK and Justice MJ: Quaking is essential for
blood vessel development. Genesis. 32:218–230. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Novikov L, Park JW, Chen H, Klerman H,
Jalloh AS and Gamble MJ: QKI-mediated alternative splicing of the
histone variant MacroH2A1 regulates cancer cell proliferation. Mol
Cell Biol. 31:4244–4255. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bian Y, Wang L, Lu H, Yang G, Zhang Z, Fu
H, Lu X, Wei M, Sun J, Zhao Q, et al: Downregulation of tumor
suppressor QKI in gastric cancer and its implication in cancer
prognosis. Biochem Biophys Res Commun. 422:187–193. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zong FY, Fu X, Wei WJ, Luo YG, Heiner M,
Cao LJ, Fang Z, Fang R, Lu D, Ji H and Hui J: The RNA-binding
protein QKI suppresses cancer-associated aberrant splicing. PLoS
Genet. 10:e10042892014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He Z, Yi J, Liu X, Chen J, Han S, Jin L,
Chen L and Song H: MiR-143-3p functions as a tumor suppressor by
regulating cell proliferation, invasion and epithelial-mesenchymal
transition by targeting QKI-5 in esophageal squamous cell
carcinoma. Mol Cancer. 15:512016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Miyoshi K, Rosner A, Nozawa M, Byrd C,
Morgan F, Landesman-Bollag E, Xu X, Seldin DC, Schmidt EV, Taketo
MM, et al: Activation of different Wnt/beta-catenin signaling
components in mammary epithelium induces transdifferentiation and
the formation of pilar tumors. Oncogene. 21:5548–5556. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wieczorek M, Paczkowska A, Guzenda P,
Majorek M, Bednarek AK and Lamparska-Przybysz M: Silencing of Wnt-1
by siRNA induces apoptosis of MCF-7 human breast cancer cells.
Cancer Biol Ther. 7:268–274. 2008. View Article : Google Scholar : PubMed/NCBI
|
